AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application. New material is indicated by an <u>underline</u>, deleted material is indicated by a <u>strikethrough</u>.

In the Claims:

- 1. (Currently amended) A method of treating rejection of a corneal transplant in a mammal, said method comprising administering to an eye of said mammal having said transplant a composition consisting essentially of comprising an antibody to tumor necrosis factor alpha.
- 2. (Original) The method of claim 1, wherein said composition is administered topically to said eye.
 - 3. (Original) The method of claim 1, wherein said mammal is a human.
- 4. (Original) The method of claim 1, wherein said antibody is a polyclonal antibody.
- 5. (Original) The method of claim 1, wherein said antibody is a monoclonal antibody.
- 6. (Original) The method of claim 1, wherein said antibody is a humanized antibody.
- 7. (Original) The method of claim 1, wherein said antibody is a biologically active fragment of an antibody to tumor necrosis factor alpha.
- 8. (Original) The method of claim 1, wherein said antibody is a heavy chain antibody.

2

Amendment in response to Office action mailed Nov. 30, 2006 U.S. Application No. 10/634,441

9. (Currently amended) The <u>method heavy chain antibody</u> of claim 8, wherein said heavy chain antibody is selected from the group consisting of a camelid antibody, a heavy chain disease antibody, and a variable heavy chain immunoglobulin.

10. (Original) The method of claim 1, wherein said composition is suspended in a pharmaceutically acceptable carrier.

11-20. (Canceled)

PHIP\535585\2

3